Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 18, 2025, InflaRx (IFRX) has a market cap of $71.161 million USD. According to our data, InflaRx is ranked No.7825 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 18, 2025 | $71.16 M |
-51.07%
|
| Dec 31, 2024 | $0.15 B |
51.53%
|
| Dec 29, 2023 | $95.98 M |
-47.42%
|
| Dec 30, 2022 | $0.18 B |
-34.87%
|
| Dec 31, 2021 | $0.28 B |
-5.37%
|
| Dec 31, 2020 | $0.30 B |
27.02%
|
| Dec 31, 2019 | $0.23 B |
-89.11%
|
| Dec 31, 2018 | $2.14 B |
73.60%
|
| Dec 29, 2017 | $1.23 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Apellis Pharmaceuticals
APLS
|
$2.28 B |
-0.000 M
|
USA
|
 Omeros Corporation
OMER
|
$0.39 B |
-0.000 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$61.57 B |
1.023 B
|
USA
|
 Amgen
AMGN
|
$149.09 B |
0.124 B
|
USA
|
 Biogen
BIIB
|
$17.36 B |
-0.001 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$125.74 B |
-0.003 M
|
USA
|
 Gilead Sciences
GILD
|
$130.32 B |
-0.001 M
|
USA
|
 Novartis
NVS
|
$219.89 B |
0.932 B
|
Switzerland
|
 AstraZeneca
AZN
|
$210.29 B |
0.735 B
|
UK
|
 Pfizer
PFE
|
$125.57 B |
0.001 M
|
USA
|
 Johnson & Johnson
JNJ
|
$379.48 B |
-0.003 M
|
USA
|
 Merck
MRK
|
$196.28 B |
0.008 M
|
USA
|
| Market Cap | = | IFRX Stock Price | * | IFRX Shares Outstanding |
| = | $1.06 | * | 67.13 M | |
| = | $71.16 M |